Inventor · disambiguated record
Bingsong Han
Also filed as: HAN BINGSONG
75 granted patents·19 pending applications·697 citations·filing 2003–2024
99Inventor score
Top patents by PatentIndex Score
94 records- 0199US10829461B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Nov 10, 2020·15 cites·12 claims
- 0299US10829462B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Nov 10, 2020·15 cites·17 claims
- 0399US10377726B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·22 cites·10 claims
- 0499US10112915B23-aryl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Oct 30, 2018·41 cites·31 claims
- 0598US11279681B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2020·Granted Mar 22, 2022·6 cites·20 claims
- 0698US10822316B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Nov 3, 2020·10 cites·15 claims
- 0798US10494354B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·17 cites·17 claims
- 0898US10494353B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·17 cites·12 claims
- 0998US10472337B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 12, 2019·17 cites·12 claims
- 1098US10428031B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 1, 2019·15 cites·20 claims
- 1198US10421731B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 24, 2019·15 cites·19 claims
- 1298US10421732B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 24, 2019·16 cites·13 claims
- 1398US10414738B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 17, 2019·16 cites·20 claims
- 1498US10239845B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Mar 26, 2019·25 cites·42 claims
- 1598US10214501B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Feb 26, 2019·20 cites·38 claims
- 1698US10214500B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Feb 26, 2019·20 cites·35 claims
- 1798US9630922B23-spiro-7-hydroxamic acid tetralins as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Apr 25, 2017·49 cites·33 claims
- 1897US11980611B2Treating sickle cell disease with a pyruvate kinase R activating compoundNOVO NORDISK HEALTHCARE AG·Filed 2022·Granted May 14, 2024·3 cites·4 claims
- 1997US11649242B2Pyrrolopyrrole compositions as pyruvate kinase (PKR) activatorsFORMA THERAPEUTICS INC·Filed 2021·Granted May 16, 2023·5 cites·4 claims
- 2097US10988450B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Apr 27, 2021·6 cites·14 claims
- 2197US10513501B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 24, 2019·11 cites·20 claims
- 2297US10494352B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·12 cites·20 claims
- 2397US10494351B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·12 cites·20 claims
- 2497US10464910B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 5, 2019·12 cites·15 claims
- 2597US10464909B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 5, 2019·12 cites·17 claims
- 2697US10457652B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 29, 2019·12 cites·18 claims
- 2797US10450283B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 22, 2019·14 cites·16 claims
- 2897US10450284B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 22, 2019·14 cites·13 claims
- 2997US10442776B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 15, 2019·15 cites·18 claims
- 3097US9637453B23-spirocyclic-6-hydroxamic acid tetralins as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted May 2, 2017·51 cites·31 claims
- 3196US11014927B2Pyrrolopyrrole compositions as pyruvate kinase (PKR) activatorsFORMA THERAPEUTICS INC·Filed 2018·Granted May 25, 2021·6 cites·3 claims
- 3295US10772874B2Compounds and compositions for the inhibition of NAMPTFORMA TM LLC·Filed 2019·Granted Sep 15, 2020·6 cites·11 claims
- 3394US10479772B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 19, 2019·6 cites·13 claims
- 3494US9676721B2Compounds and compositions for the inhibition of NAMPTBAIR KENNETH W·Filed 2011·Granted Jun 13, 2017·33 cites·7 claims
- 3593US10647695B2Compounds and compositions for the inhibition of NAMPTFORMA TM LLC·Filed 2019·Granted May 12, 2020·5 cites·7 claims
- 3693US10272072B2Compounds and compositions for the inhibition of NAMPTFORMA TM LLC·Filed 2016·Granted Apr 30, 2019·11 cites·19 claims
- 3793US9745253B2Alpha-cinnamide compounds and compositions as HDAC8 inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Aug 29, 2017·10 cites·53 claims
- 3892US11891365B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2021·Granted Feb 6, 2024·1 cites·23 claims
- 3992US9169209B2Compounds and compositions for the inhibition of NAMPTBAIR KENNETH W·Filed 2011·Granted Oct 27, 2015·25 cites·22 claims
- 4091US11547701B2Compounds and compositions for the inhibition of NAMPTVALO HEALTH INC·Filed 2020·Granted Jan 10, 2023·2 cites·11 claims
- 4191US11279687B2Compounds and compositions for the inhibition of NAMPTVALO HEALTH INC·Filed 2020·Granted Mar 22, 2022·2 cites·9 claims
- 4291US10456382B2Compounds and compositions for the inhibition of NAMPTFORMA TM LLC·Filed 2018·Granted Oct 29, 2019·7 cites·20 claims
- 4391US10329275B2Compounds and compositions for the inhibition of NAMPTFORMA TM LLC·Filed 2018·Granted Jun 25, 2019·8 cites·10 claims
- 4490US9555039B2Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)BAIR KENNETH W·Filed 2011·Granted Jan 31, 2017·13 cites·19 claims
- 4590US2024391922A1Pyrrolopyrrole compositions as pyruvate kinase (pkr) activatorsNovo Nordisk Heathcare AG·Filed 2024·Application pending·0 cites
- 4689US11274084B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2020·Granted Mar 15, 2022·1 cites·18 claims
- 4789US10538496B2Methods using HDAC11 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Jan 21, 2020·3 cites·5 claims
- 4889US10508088B2Methods using HDAC11 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 17, 2019·3 cites·11 claims
- 4988US12071440B2Pyrrolopyrrole compositions as pyruvate kinase (PKR) activatorsNOVO NORDISK HEALTHCARE AG·Filed 2023·Granted Aug 27, 2024·0 cites·4 claims
- 5088US11247987B2Inhibiting ubiquitin specific peptidase 30FORMA THERAPEUTICS INC·Filed 2018·Granted Feb 15, 2022·3 cites·24 claims
Showing the top 50 of 94 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Bingsong Han files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →